Roanna Ruiz has given her Buy rating due to a combination of factors that highlight Lexicon Pharmaceuticals’ strategic advancements and potential for value growth. One significant reason is the ...
Lexicon Pharmaceuticals (NASDAQ:LXRX) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent ...
Lexicon Pharmaceuticals shares have been halted all day as a Food and Drug Administration advisory committee was scheduled to vote on Zynquista as an adjunct to insulin therapy for glycemic ...
Lexicon Pharmaceuticals received a negative vote from a Food and Drug Administration advisory committee for Zynquista as an adjunct to insulin therapy for glycemic control in adults with Type 1 ...
THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference.
Oct 31 (Reuters) - Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' (LXRX.O), opens new tab add-on treatment to insulin ...
THE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Viatris Inc. (Nasdaq: VTRS) has obtained an exclusive license from Lexicon ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback